NCT05244798 is a Phase 3 clinical trial of Sintilimab in Esophageal Squamous Cell Carcinoma, sponsored by Sichuan Cancer Hospital and Research Institute.

Who is sponsoring NCT05244798?

NCT05244798 is sponsored by Sichuan Cancer Hospital and Research Institute.

What drugs are being tested in NCT05244798?

Interventions in NCT05244798: Sintilimab, radiotherapy, Chemotherapy.

What condition does NCT05244798 study?

NCT05244798 studies Esophageal Squamous Cell Carcinoma.

Is NCT05244798 still recruiting?

NCT05244798 is currently not yet recruiting. Last updated 25 October 2022.

Last reviewed 2022-10-25 · How we verify

NCT05244798

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Not yet recruiting Phase 3 Last updated 25 October 2022

What this trial tests

Phase 3 trial testing Sintilimab in Esophageal Squamous Cell Carcinoma in 420 participants. Not yet recruiting.

Timeline

1 November 2022

Primary endpoint
31 December 2025

31 December 2026

Quick facts

Lead sponsor	Sichuan Cancer Hospital and Research Institute
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	420
Start date	1 November 2022
Primary completion	31 December 2025
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

Sintilimab — full drug profile →
radiotherapy — full drug profile →
Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

Sichuan Cancer Hospital and Research Institute

Who can join

Adults 18 to 75, any sex, with Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparative analysis of patients with resectable locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy combined sintilimab versus neoadjuvant chemoradiotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Recent developments in immunotherapy for gastrointestinal tract cancers.
Chong X, Madeti Y, Cai J, Li W, et al · · 2024 · cited 52× · PMID 39123202 · DOI 10.1186/s13045-024-01578-x
Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
Li Q, Liu T, Ding Z. · · 2022 · cited 43× · PMID 36569908 · DOI 10.3389/fimmu.2022.1051841
Current status and perspectives of esophageal cancer: a comprehensive review.
Jiang W, Zhang B, Xu J, Xue L, et al · · 2025 · cited 28× · PMID 39723635 · DOI 10.1002/cac2.12645
Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.
Li N, Sohal D. · · 2023 · cited 22× · PMID 37995002 · DOI 10.1007/s00262-023-03566-5
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.
Liu Y. · · 2023 · cited 16× · PMID 37753366 · DOI 10.3748/wjg.v29.i34.5020
Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
Gervaso L, Ciardiello D, Oliveira RA, Borghesani M, et al · · 2024 · cited 12× · PMID 38782539 · DOI 10.1136/jitc-2023-008027
Targeting esophageal carcinoma: molecular mechanisms and clinical studies.
Wang W, Ye L, Li H, Mao W, et al · · 2024 · cited 7× · PMID 39415846 · DOI 10.1002/mco2.782
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research.
Kumar R, Kim J, Deek MP, Eskander MF, et al · · 2023 · cited 7× · PMID 37504333 · DOI 10.3390/curroncol30070473

Verify or expand the search:

Other trials of Sintilimab

Trials testing the same drug.

NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other Sichuan Cancer Hospital and Research Institute trials

Trials by the same sponsor.

NCT07269912 — Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer · not yet recruiting
NCT07082699 — The Efficacy of Antegrade and Retrograde Enemas Management in Low Anterior Resection Syndrome and Improving the Rate of · NA · not yet recruiting
NCT06939764 — Application of the sG8 Scale in Real-World Geriatric Oncology Patients · not yet recruiting
NCT06717854 — Retrograde and Antegrade Enema for Prevention of LARS After LAR: a Randomized Controlled Trial · NA · not yet recruiting
NCT06860685 — Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05244798 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan Cancer Hospital and Research Institute
Last refreshed: 25 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05244798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing